Global Immunomodulating Tenders and GPN from across the Globe

Antitumor and Immunomodulating Agents

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for Drugs with the Active Ingredient Dasatinib (Atc Code: L01ea02).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Filgrastim (Atc Code: L03aa02).

Conclusion of a Non-Exclusive Discount Agreement in Accordance with § 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Rituximab (Atc Code: L01fa01).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Goserelin (Atc Code: L02ae03).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Pegfilgrastim (Atc Code: L03aa13).

Conclusion of a Non-Exclusive Discount Agreement According to Section 130A Paragraph 8 Sgb V for Medicinal Products with the Active Ingredient Golimumab (Atc Code: L04ab06).

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for Medicines with the Active Ingredient Glatiramer Acetate (Atc Code: L03ax13), with the Exception o...

Lp Containing Lorlatinib 2024

Interferony Beta 1A 2024